Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Leerink Partners Analyst Says

Hims & Hers Health (NYSE:HIMS) had its price target lifted by investment analysts at Leerink Partners from $24.00 to $40.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “market perform” rating on the stock. Leerink Partners’ price objective suggests a potential downside of 4.45% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Piper Sandler lifted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Bank of America boosted their price target on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $34.47.

Hims & Hers Health Trading Up 5.0 %

Shares of Hims & Hers Health stock opened at $41.87 on Tuesday. The business has a fifty day simple moving average of $35.89 and a two-hundred day simple moving average of $26.36. The firm has a market capitalization of $9.15 billion, a P/E ratio of 95.15 and a beta of 1.35. Hims & Hers Health has a 12 month low of $11.20 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,578 shares of company stock valued at $38,080,320 over the last quarter. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the company. Main Management ETF Advisors LLC purchased a new position in Hims & Hers Health during the third quarter valued at approximately $672,000. Robeco Institutional Asset Management B.V. purchased a new position in Hims & Hers Health during the third quarter valued at approximately $604,000. Royce & Associates LP raised its position in Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares in the last quarter. Versor Investments LP purchased a new position in Hims & Hers Health during the third quarter valued at approximately $634,000. Finally, International Assets Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $6,790,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.